PURE Bioscience Appoints Dave Pfanzelter Chairman of the Board
2013年5月17日 - 10:10PM
Marketwired
PURE Bioscience (OTCQB: PURE), creator of the
patented silver dihydrogen citrate (SDC) antimicrobial, appointed
food industry leader Dave Pfanzelter as chairman of the board.
Pfanzelter has been a member of the board since February 2013 and
had previously served on the PURE Bioscience Advisory Panel. The
position of chairman had been held by PURE's president and CEO,
Michael L. Krall, since 1993.
Pfanzelter previously served as senior vice president of Kellogg
Company, president of Kellogg's Specialty Channels, and president
of Kellogg Canada while also serving as part of the Kellogg
Executive Committee and Global Leadership Team. He has also served
on the board of the International Food Service Manufacturer's
Association as chairman and a member of its executive committee.
Pfanzelter currently serves on the board of directors of Doctor's
Associates, the parent company of Subway Restaurants, as well as on
Wrigley Foods' Advisory Board of Directors.
Pfanzelter stated: "I am honored to be named chairman of PURE's
board. The company has endured a rough road during the extensive
processes of R&D, regulatory approvals and product development
and is engaged in notably long sales cycles. Despite these
challenges, the board remains confident in PURE's ability to
overcome the high hurdle of market acceptance. I look forward to
working closely with Michael and the PURE management team."
Krall added: "Dave is a great fit for the future of SDC and PURE
Bioscience, and I welcome the opportunity to expand our leadership
resources while strengthening our corporate governance. Dave's
extensive experience is invaluable to PURE as we move through the
final steps of evaluation by several key potential customers,
including those in the food industry and within the military."
"We acknowledge the need to right-size our organization while
still moving aggressively toward closing sales in our target
markets yet staying nimble enough to successfully operate the
business," continued Krall. "To that end, we have reduced costs and
personnel in all departments other than sales and marketing as we
continue the push toward meaningful revenues. We've also
established high-capacity outsourcing options for manufacturing to
remain positioned to timely fill orders as necessary."
PURE has cut total wage expenditures by more than 30% through
the elimination of manufacturing, research and development,
administrative and executive positions. The company has also
reduced G&A expenses related to professional services,
including legal and consulting fees, public relations and investor
relations. Furthermore, PURE's corporate officers and directors
have elected to defer the majority of cash compensation, effective
immediately.
About PURE Bioscience, Inc. PURE
Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health
challenges, including Staph (MRSA) and Carbapenem-resistant
Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high
efficacy/low toxicity bioscience technologies, including its silver
dihydrogen citrate-based antimicrobials, represent innovative
advances in diverse markets and lead today's global trend toward
industry and consumer use of "green" products while providing
competitive advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
Forward-looking Statements This press
release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate,"
"expect," "intend," "project" or similar expressions. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's cash
position and liquidity requirements, the Company's failure to
implement or otherwise achieve the benefits of its proposed
initiatives and business plans, acceptance of the Company's current
and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in
the Company's periodic report filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Investor Relations Contact: Ron Both Liolios Group, Inc.
Tel 949-574-3860 Email Contact
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024